Business Highlights
By The Associated Press - AP - Thu Sep 25, 5:00PM CDT
___
Valeant (VRX) Sends Letter to Allergan, Provides Q3 Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 3:38PM CDT
In a move to strengthen its acquisition offer for Allergan (AGN), Valeant Pharmaceuticals International, Inc. (VRX) announced that it has sent a letter to the former providing an update on its expected third-quarter results.
Valeant: Glaucoma Drug Is Potential Blockbuster
at Investor's Business Daily - Thu Sep 25, 12:47PM CDT
The Bausch & Lomb division of Valeant Pharmaceuticals International (VRX) announced positive late-stage trial results of a new glaucoma drug Thursday and projected it could sell more than $1 billion a year. Valeant popped over 6% in morning trading...
Allergan Issues Statement Regarding Recent Valeant Correspondence
Business Wire - Thu Sep 25, 8:00AM CDT
Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company"
Acquisitions, Distributions, Partnerships, and Recognitions - Research Reports on Dr Pepper Snapple, AmericanTower, Allergan, Zoetis and Aetna
PR Newswire - Thu Sep 25, 7:30AM CDT
Today, Analysts Review released its research reports regarding Dr Pepper Snapple Group, Inc. (NYSE: DPS), American Tower Corporation (NYSE: AMT), Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6743-100free.
Valeant pitches potential eye drug, research focus
By TOM MURPHY - AP - Thu Sep 25, 7:28AM CDT
Valeant Pharmaceuticals is drawing attention to a potential glaucoma treatment and its focus on product development, as the Canadian drugmaker continues to build its case to investors for a takeover of Botox-maker Allergan.
Allergan and Salix Pharmaceuticals Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 3:45PM CDT
Allergan Inc. (AGN) and Salix Pharmaceuticals Ltd. (SLXP) were up after a report from The Wall Street Journal indicated that the former has renewed its attempts to acquire the latter.
Allergan Rises 4.20% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Sep 24, 3:40PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $169.50 to a high of $176.75. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $171.27 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Valeant Ends Prince Charming Act; Allergan Hopes Rise
at Investor's Business Daily - Wed Sep 24, 3:23PM CDT
Valeant Pharmaceuticals (VRX) shares popped on upbeat guidance and as the addition of Actavis (ACT) to the Allergan-Valeant-Salix triangle lifted Valeant's chances for an Allergan takeover. Valeant said it expects to beat third-quarter analyst views...
Company News for September 24, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 9:10AM CDT
Companies in the News are: KMX,ASNA,AGN,SLXP,FB
Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director
CNW Group - Wed Sep 24, 8:05AM CDT
Overall Same Store Organic Growth (unadjusted for generics) Expected to Exceed 15% in Third Quarter
Premature Ejaculation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Wed Sep 24, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9p25qq/premature) has announced the addition of the "Premature Ejaculation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - SK Chemicals Co., Ltd. - Yungjin Pharm Ind. Co., Ltd. - Plethora Solutions Holdings plc - NeuroHealing Pharmaceuticals Inc. - Furiex Pharmaceuticals, Inc. - Dong-A Socio Group Drug Profiles - tramadol hydrochloride - (lidocaine prilocaine) - dapoxetine hydrochloride - tramadol hydrochloride - onabotulinumtoxin A - DA-8031 - IX-01 - modafinil - NCE-405 - YPE-1706 For more information visit http://www.researchandmarkets.com/research/9p25qq/premature
Jim Cramer's Top Stock Picks: MWE AGN AAPL AZO
at The Street - Wed Sep 24, 5:00AM CDT
Cramer says MarkWest Energy Partners is a terrific growth story while he has nothing but good things to say about Allergan, Apple and AutoZone.
Jim Cramer's 'Mad Money' Recap: Why You Must Stay the Course
at The Street - Tue Sep 23, 7:18PM CDT
You have to be ready to seize the opportunities that are being created by a declining market, Cramer advises.
Ackman forewarns Allergan
at Investor's Business Daily - Tue Sep 23, 5:45PM CDT
William Ackman of Pershing Square Capital Management wrote a letter to Allergan's (AGN)board saying that a deal with Salix Pharmaceuticals (SLXP), which would not have to be approved by shareholders if it's all cash, could be a breach of fiduciary...
Stocks Finish Lower Among Takeover Rumors
at Investor's Business Daily - Tue Sep 23, 5:06PM CDT
Stocks finished the day down moderately, with the Nasdaq and the S&P 500 lower for the third straight day. Volume was running lighter than the previous day, according to preliminary figures. The Nasdaq was down 0.4%; the S&P 500 fell 0.6% and the Dow...
Carmax and Medtronic are big market movers
AP - Tue Sep 23, 3:22PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Stocks Fall To Session Lows; Vipshop Bucks The Trend
at Investor's Business Daily - Tue Sep 23, 2:00PM CDT
Selling picked up the pace in the major averages in late-afternoon trading Tuesday. The Dow Jones industrial average fell 0.6%; the S&P 500 gave up 0.4% and the Nasdaq lost 0.3%. NYSE and Nasdaq volume was tracking about 5% to 10% lower than Monday's...
Stocks Fall Modestly; New Issue Alibaba Extends Losses
at Investor's Business Daily - Tue Sep 23, 10:56AM CDT
Major averages opened lower and stayed there about two hours into Tuesday's session. Losses were mild, though, on a busy day of headline flow. The Dow Jones industrial average lost 0.3%; the S&P 500 fell 0.2% and the Nasdaq eased less than 0.1%. NYSE...